Document Detail

A comparison of folic Acid pharmacokinetics in obese and nonobese women of childbearing age.
MedLine Citation:
PMID:  21572389     Owner:  NLM     Status:  In-Data-Review    
BACKGROUND: : Although maternal folate deficiency during the periconceptional period represents a major risk factor for neural tube defects, obesity has been recognized as an additional risk factor. Studies have identified an increased risk for neural tube defect-affected births among obese mothers even after adjusting for folic acid supplementation. However, although folic acid intake may have been at the recommended dose in these samples, blood folate concentrations were not monitored to ensure that protective levels were reached. Hence, there is a need to compare folic acid pharmacokinetics in obese and nonobese women of childbearing age.
METHODS: : Healthy obese (n = 12) and nonobese (n = 12) women of childbearing age volunteered to participate. Each obese participant was matched to a nonobese participant and assigned an equivalent dose of folic acid per kilogram body weight. Folic acid was orally administered after a 6-hour fast, and blood samples were taken over a 10-hour period to evaluate pharmacokinetic parameters.
RESULTS: : Area under the time-concentration curve (AUC) was found to be significantly higher in the obese group (P = 0.008). Defining AUC as a function of dose per kilogram lean body weight (LBW) was found to be a stronger predictor than dose per kilogram total body weight (r = 0.90 and 0.76, respectively).
CONCLUSIONS: : This indicates that the body tightly controls systemic exposure to folic acid, with 90% of the variability in AUC controlled by the dose per kilogram LBW. Periconceptional supplementation recommendations may need to be adjusted to account for LBW differences in the obese population.
Seth J Stern; Ilan Matok; Bhushan Kapur; Gideon Koren
Related Documents :
15331379 - Glycine intake decreases plasma free fatty acids, adipose cell size, and blood pressure...
17242489 - Stearoyl-coa desaturase--a new player in skeletal muscle metabolism regulation.
10381339 - Preliminary characterization of yor180cp: identification of a novel peroxisomal protein...
15110319 - Identification of fatty aldehyde dehydrogenase in the breakdown of phytol to phytanic a...
12032169 - Pparalpha suppresses insulin secretion and induces ucp2 in insulinoma cells.
9030189 - Thia fatty acids, metabolism and metabolic effects.
717179 - Effect of dimaprit on gastric acid secretion in conscious cats.
15087119 - Identification of the tbx5 transactivating domain and the nuclear localization signal.
20000509 - Ph-dependent sorption of acidic organic chemicals to soil organic matter.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Therapeutic drug monitoring     Volume:  33     ISSN:  1536-3694     ISO Abbreviation:  Ther Drug Monit     Publication Date:  2011 Jun 
Date Detail:
Created Date:  2011-05-16     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  7909660     Medline TA:  Ther Drug Monit     Country:  United States    
Other Details:
Languages:  eng     Pagination:  336-40     Citation Subset:  IM    
From the *Department of Pharmacology and Toxicology, Faculty of Medicine, University of Toronto; †Division of Clinical Pharmacology and Toxicology, The Hospital for Sick Children; ‡Department of Clinical Pathology, Sunnybrook Health Science Centre; and §Department of Laboratory Medicine and Pathobiology, Faculty of Medicine, University of Toronto, Toronto, Canada.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Monitoring of mycophenolic Acid predose concentrations in the maintenance phase more than one year a...
Next Document:  MT1-MMP cleaves Dll1 to negatively regulate Notch signalling to maintain normal B-cell development.